- Home
- EXTR vs AKRO Comparison
EXTR vs AKRO Comparison
Compare EXTR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- AKRO
- Stock Information
- Founded
- EXTR 1996
- AKRO 2017
- Country
- EXTR United States
- AKRO United States
- Employees
- EXTR N/A
- AKRO N/A
- Industry
- EXTR Telecommunications Equipment
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- EXTR Telecommunications
- AKRO Health Care
- Exchange
- EXTR Nasdaq
- AKRO Nasdaq
- Market Cap
- EXTR 2.6B
- AKRO 3.6B
- IPO Year
- EXTR 1999
- AKRO 2019
- Fundamental
- Price
- EXTR $22.32
- AKRO $43.46
- Analyst Decision
- EXTR Strong Buy
- AKRO Strong Buy
- Analyst Count
- EXTR 6
- AKRO 8
- Target Price
- EXTR $21.42
- AKRO $80.38
- AVG Volume (30 Days)
- EXTR 1.3M
- AKRO 945.4K
- Earning Date
- EXTR 10-29-2025
- AKRO 11-07-2025
- Dividend Yield
- EXTR N/A
- AKRO N/A
- EPS Growth
- EXTR N/A
- AKRO N/A
- EPS
- EXTR N/A
- AKRO N/A
- Revenue
- EXTR $1,140,067,000.00
- AKRO N/A
- Revenue This Year
- EXTR $10.26
- AKRO N/A
- Revenue Next Year
- EXTR $7.48
- AKRO N/A
- P/E Ratio
- EXTR N/A
- AKRO N/A
- Revenue Growth
- EXTR 2.05
- AKRO N/A
- 52 Week Low
- EXTR $10.10
- AKRO $21.34
- 52 Week High
- EXTR $22.89
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- EXTR 63.56
- AKRO 36.83
- Support Level
- EXTR $21.50
- AKRO $42.56
- Resistance Level
- EXTR $22.89
- AKRO $46.18
- Average True Range (ATR)
- EXTR 0.60
- AKRO 1.80
- MACD
- EXTR 0.01
- AKRO -0.19
- Stochastic Oscillator
- EXTR 75.22
- AKRO 13.42
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.